Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: GlobalData
$125.00
Provider: New Constructs, LLC
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Isis Pharmaceuticals Inc announces positive opinion on european orphan drug designation for ISIS-TTR


Friday, 14 Feb 2014 01:32pm EST 

Isis Pharmaceuticals Inc:Says that the Committee for Orphan Medicinal Products (COMP) has adopted a positive opinion recommending ISIS-TTR for designation as an orphan medicinal product for the treatment of ATTR-Amyloidosis to the European Commission.The opinion will be subject to review by the EC, which ultimately grants the decision on orphan drug designation. ATTR-Amyloidosis, or TTR amyloidosis, is a severe and rare genetic disease characterized by progressive dysfunction of peripheral nerve and/or heart tissues.Says ISIS-TTR is an antisense drug in development with GlaxoSmithKline (GSK), which has an option to exclusively license the ISIS-TTRRxprogram. 

Company Quote

59.3
1.82 +3.17%
10:18am EST